A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Epistemonikos ID: e5c2d5c16508689496889dde2b714b5345d7c0b0
First added on: May 10, 2024